Welcome to the CAR-TCR Summit Europe 2021
Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe, Effective & Affordable Advanced Therapies
With CAR-TCR therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for.
The CAR-TCR Summit Europe (16th-18th February 2021) will unravel the technical challenges across R&D, translation, scale and delivery to provide your team with the platform to learn, collaborate and gain actionable insights to advance your therapy for clinical and commercial success.
This year's focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle, providing more comprehensive analysis from 55+ expert speakers across 3 streams of content including:
Research & Development Track:
- Explore the emerging CAR-X landscape with Glycostem & Carisma Therapeutics
- Breach the solid tumour microenvironment with Refuge Biotech & Atara Biotherapeutics
- Optimise target identification with Celyad & Anocca AB
- Investigate next-generation gene engineering techniques with Precision Biosciences
Translation Track:
- Develop 'off-the-shelf' platforms with Leucid Bio
- Provide a mechanistic rationale for combination therapies with Agenus & Ziopharm Oncology
- Discuss 'gold standards' and innovations in assay development GlaxoSmithKline & bluebird bio
- Understand and minimise toxicity with Kite: A Gilead Company & The NHS
Manufacturing & Commercialisation Track:
- Advance automation for cheaper, faster manufacturing with Gracell Biotechnologies & Glycostem
- Gain regulatory guidance to initiate clinical trials in Europe from MHRA & Norwegian Medicines Authority
- Maximise real-world evidence for value demonstration, and innovative reimbursement models with Janssen
- Expedite batch release and maintain high-quality products with Novartis & Immatics
For agenda details and full speaker line up, find out more here
